GlassScriptPhysician profile
Feng Jiang
NPI 1457640807
$2,683.33
in general payments reported to CMS, 2019-2025
45 companies · $454 in 2025
The $454 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $121 · 2021: $308 · 2022: $243 · 2023: $408 · 2024: $553 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.00 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $407.07 | 2019-2025 | |
| Astellas Pharma US INC | $184.94 | 2019-2025 | Xospata, Xtandi, Padcev |
| Genentech USA, INC. | $161.89 | 2019-2025 | Perjeta, Phesgo, Tecentriq |
| Janssen Biotech, INC. | $139.23 | 2019-2025 | Erleada, Akeega, Balversa |
| Celgene Corporation | $132.61 | 2019-2025 | Reblozyl |
| Seagen INC. | $132.21 | 2021-2022 | |
| Amgen INC. | $107.00 | 2019-2024 | Prolia, Evenity |
| Daiichi Sankyo INC. | $92.61 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Merck Sharp & Dohme LLC | $91.64 | 2019-2025 | Keytruda, Welireg |
| Pfizer INC. | $85.20 | 2019-2025 | |
| Incyte Corporation | $83.69 | 2023-2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $62.95 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $62.84 | 2019-2025 | Opdualag |
| Genzyme Corporation | $59.57 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $58.78 | 2020-2023 | Imbruvica |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feng Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.